Skip to main content

AbbVie Has Tentative Plans To Exit Testosterone MDL

AbbVie Has Tentative Plans To Exit Testosterone MDL

AbbVie Has Tentative Plans To Exit Testosterone MDL

Introduction

Closely following Actavis and Endo, AbbVie Inc. recently filed a statement in Illinois federal court about reaching on a tentative deal to settle all Testosterone lawsuits pending in the multidistrict litigation against them.

U.S. District Judge Matthew Kennelly confirmed in an order that the cases pending against Abbvie & its subsidiaries Abbott Laboratories, Solvay Pharmaceuticals Inc. and Unimed Pharmaceuticals LLC would enter a global settlement phase under confidential terms. AbbVie Inc. faces more than 4,500 lawsuits claiming the company did not caution about the risks of heart attacks, strokes and blood clots that could occur from using their Testosterone Replacement Therapy (TRT) drug AndroGel.

Endo International recently announced to settle all TRT claims against them in a separate track from the federal MDL. In June 2018, the company had agreed upon a $200 million tentative settlement for about 1,300 lawsuits. Actavis had admitted settling about 500 Androderm cases filed against it in July this year. Lawsuits filed against TRT providers accuse them of hiding health risks of injuries including heart attack, stroke, deep vein thrombosis, pulmonary embolism, and sudden death. Currently, there are more than 5,900 lawsuits pending in the testosterone multidistrict litigation (MDL No. 2545; In Re: Testosterone Replacement Therapy Products Liability Litigation) presided by Judge Matthew Kennelly in the Northern District of Illinois.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Study Finds Toxic Metals in E-Cigs and U-Cigs Vapors

Categories: E-Cigarette: JUUL

As health concerns about e-cigarette use escalate, emerging research suggests that a newer class of vaping products—ultrasonic cigarettes or u-cigarettes—may pose even greater risks.

A study published in Environmental Health Perspectives in…

Appeals Court Upholds $611M Roundup Verdict

Categories: Roundup

A Missouri appeals court has upheld a massive Roundup verdict originally totaling $1.5 billion, but significantly reduced the final amount Bayer and its Monsanto unit must pay to $611 million.

The case involved three plaintiffs from New…

Valsartan “Wave 2” Bellwether Trial Schedule Set by Court

Categories: Valsartan

As the first Valsartan bellwether trial approaches in September 2025, the federal judge overseeing the multidistrict litigation (MDL) is preparing a second set of trials.

This move comes in anticipation of the possibility that parties may…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!